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Abstract The density of skeletal muscle caveolae is increased in
Duchenne muscular dystrophy and its genetic homologue, the
mdx mouse. This structural change is significant as it may
indicate muscle regeneration. We identified in mdx mouse tibialis
anterior muscles significantly increased levels of caveolin-3, the
chief protein in muscle caveolae, and reduced levels of neuronal
nitric oxide synthase, an enzyme regulated by caveolin-3. Similar
changes occurred in the corresponding mRNA levels. These data
suggest that induction of caveolin-3 occurs and this may at least
partly be responsible for increased number of caveolae, altered
nNOS-caveolin cycle, and regeneration of dystrophic muscles.
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1. Introduction
Caveolins, 21^24 kDa proteins, are the chief structural
components of caveolae, distinct cholesterol- and sphingo-
lipid-rich vesicular invaginations of the plasma membranes
[1]. Caveolins form homo-oligomeric complexes with each
other. They also bind and regulate several di¡erent signaling
molecules such as calcium-dependent nitric oxide synthases,
G-proteins, Ha-Ras and Src family of tyrosine kinases [1,2].
Caveolin-3 is a newly identi¢ed member of the caveolin
family of proteins. It is speci¢cally expressed in skeletal, car-
diac and smooth muscles [3,4]. In skeletal muscles, caveolin-3
binds and regulates neuronal nitric oxide synthase (nNOS)
[5,6] and phosphofructokinase M, a key regulatory enzyme
of glycolytic pathway [7]. Caveolin-3 is transiently associated
with T-tubules during development [8]. Caveolin-3 is also as-
sociated with dystrophin [4], a protein that is mutated or
absent in Duchenne muscular dystrophy (DMD). Defects in
the expression of dystrophin-associated proteins cause the
various forms of muscular dystrophies [9]. A recent study
shows that mutated caveolin-3 is responsible for the develop-
ment of a speci¢c form of limb-girdle muscular dystrophy
[10].
Morphological studies have identi¢ed a characteristic in-
crease in the number of caveolae in DMD [11] and mdx
mice [12]. We have studied the expressions of caveolin-3 and
nNOS in mdx mice, animals that do not express dystrophin
and are the genetic homologues of DMD [13]. While the ex-
pression of nNOS was reduced, caveolin-3 levels increased in
dystrophic muscles that successfully compensate for the lack
of dystrophin. These data suggest that caveolin-3 expression is
induced and this, just like induction of utrophin [14], may aid
muscle regeneration.
2. Materials and methods
2.1. Laboratory animals
Control (C57BL/10SnJ) and mdx (C57BL/10ScSn Dmdmdx ) mice
were purchased from Jackson Laboratories and were use at 1 year
of age. Skeletal muscles were dissected, weighed, rapidly frozen and
stored at 380‡C until use.
2.2. NOS activity and Western blots
NOS activity was determined by the citrulline assay [15]. Caveolin-3
and nNOS proteins were detected by Western blot analysis as de-
scribed before [15] using a variety of polyclonal (C38330, N31030,
N53130) and monoclonal (C38320, N31020) antibodies from Trans-
duction Laboratories, Lexington, KY. Quantitative analysis of West-
ern blots was performed by Kodak BioMax 1D Image Analysis Soft-
ware.
2.3. Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated according to Chomczynski and Sacchi [16].
Three Wg total RNA was reverse transcribed with Superscript Pream-
pli¢cation system (Gibco BRL) according to the manufacturer’s spec-
i¢cations. PCR ampli¢cations were carried out using the following
parameters: 5 min denaturation at 94‡C, 2 min annealing at 62‡C,
followed by 35 cycles of 1 min at 72‡C, 40 s at 94‡C and 40 s at 62‡C,
with a ¢nal extension of 10 min at 72‡C. For PCR ampli¢cation of a
271 bp nNOS and a 373 bp nNOSW products the following primer
pair was used: CAC CAG CAC CTT TGG CAA TGG AG (sense)
and AAA GGC ACA GAA GTG GGG GTA (antisense). For PCR
ampli¢cation of a 447 bp caveolin-3 product the primers were: ATG
ATG ACC GAA GAG CAC ACG G (sense) and CCT TCG CAG
CAC CAC CTT AAT G (antisense). A L-actin primer set for RT-
PCR was purchased from Stratagene (Cat. #302110).
2.4. Northern blot analysis
Total RNA (30 Wg) was separated on a 1% agarose gel, transferred
to a nylon membrane, air dried, pre-hybridized for 20 min at 65‡C in
Rapid-hyb bu¡er (Amersham) and then incubated for 3 h at 65‡C
with [K-32P]dCTP-labeled probes (mouse nNOS, mouse caveolin-3
and mouse L-actin PCR fragments). After extensive washing, auto-
radiography was performed at 380‡C for 16 h.
3. Results
We have determined the expression of nNOS and caveolin-3
proteins by Western blot analysis in tibialis anterior (TA)
muscles of mdx mice. In agreement with previous studies
[17], our data indicate that the nNOS levels are greatly re-
duced in both the membrane (Fig. 1A) and the soluble frac-
tions of mdx muscles (Fig. 1B). A second probe of the same
blots with an anti-caveolin-3 monoclonal antibody revealed
the presence of caveolin-3 protein in the membrane fractions
of control TA muscles (Fig. 1A), and to a lesser extent in the
soluble fractions of the same muscles (Fig. 1B). Identical re-
sults were obtained with an anti-caveolin-3 polyclonal anti-
body (not shown). It became also apparent from these studies
that much more caveolin-3 protein is present in both the
membrane and soluble fractions of mdx TA muscles (Fig.
1A,B). These studies suggested that the expression of nNOS
and caveolin-3 may change reciprocally in mdx muscles. Ver-
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i¢cation of this ¢nding required unequivocal identi¢cation
and quantitation of these proteins.
We consistently identi¢ed in Western blots two protein
bands (160 and 164 kDa) that speci¢cally reacted with an
anti-brain NOS monoclonal antibody (Fig. 1A,B) and two
other anti-brain NOS polyclonal antibodies (data not shown).
Previous studies of nNOS expression in mdx mice did not
describe the simultaneous expression of two nNOS isoforms
[17]. Nevertheless, the predominant expression of an alterna-
tively spliced muscle speci¢c nNOS isoform, nNOSW that is
approximately 4 kDa larger than nNOS, is well established
[18]. Since the molecular masses of 160 and 164 kDa of the
proteins that reacted with anti-brain NOS antibodies corre-
sponded to the expected sizes of nNOS and nNOSW, respec-
tively, the possibility that these two nNOS isoforms are co-
expressed was further investigated by RT-PCR.
The muscle speci¢c nNOSW is di¡erent from nNOS in that
it contains a 102 bp insert between amino acid residues 839
and 840 [18]. This results in the expression of a nNOSW pro-
tein that is 34 amino acid residues larger than nNOS. We used
a pair of PCR primers to amplify the cDNA fragment that
includes this alternatively spliced segment. This primer pair
was expected to amplify a 271 bp cDNA fragment of nNOS
and a 373 bp cDNA fragment of nNOSW simultaneously if
both mRNA are present together. Fig. 1C shows that this
was, in fact, the case. This one set of primer pair ampli¢ed
the expected two cDNA fragments in both control and mdx
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Fig. 1. nNOS and caveolin-3 protein and mRNA levels in mdx
mouse muscles. A: Western blot analysis of nNOS and caveolin-3
protein levels in the membrane fraction of control and mdx mouse
TA muscles. The nNOS proteins were detected with an anti-brain
NOS monoclonal antibody (Transduction Laboratory, Lexington,
KY) and caveolin-3 protein was detected with an anti-caveolin-3
monoclonal antibody (Transduction Laboratory, Lexington, KY).
This antibody (clone 26) was originally produced and characterized
by Song et al. [4]. Lanes 1^3, control TA membranes from three an-
imals; lane 4, nNOS standard; lanes 5^7, mdx TA membranes from
three animals. B: Western blot analysis of nNOS and caveolin-3
protein levels in the soluble fraction of control and mdx mouse TA
muscles. Detections as described in A. Lanes 1^3, control TA; lane
4, nNOS standard; lanes 5^7, mdx TA. C: cDNA fragments of cav-
eolin-3 and nNOS ampli¢ed by PCR after reverse transcription of
TA mRNA. Lanes 1 and 2, 447 bp caveolin-3 cDNA fragment am-
pli¢ed from control (lane 1), and mdx (lane 2) muscles. Lane 3, 123
bp ladder. Lanes 4 and 5, 271 bp nNOS and 373 bp nNOSW cDNA
fragments ampli¢ed from control (lane 4) and mdx (lane 5) muscles.
D: Northern blot analysis of nNOS and caveolin-3 mRNA levels in
control (lanes 1, 3 and 5) and mdx (lanes 2, 4 and 6) mouse leg
muscles.
Fig. 2. Quantitative changes in NOS activity, nNOS protein and
caveolin-3 protein levels in mdx mouse TA muscles. Top panel:
NOS activity. Middle panel: nNOS proteins. The data represent the
sum of two proteins, nNOS and nNOSW. Lower panel: Caveolin-3
protein. All data were normalized to show percentages relative to
controls (100%). Abbreviations: M, membrane fraction; S, soluble
fraction. Statistics : mean values þ S.E.M., n = 6.
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muscles, although the intensity of these bands was much
stronger in controls than dystrophic muscles. Thus, nNOS
and nNOSW mRNAs are co-expressed in control muscles
and the expressions of both of these messages are reduced
in dystrophic muscles. We also investigated the expression
of caveolin-3 mRNA in control and mdx muscles. RT-PCR
ampli¢cation of a 447 bp caveolin-3 cDNA fragment revealed
the presence of signi¢cantly increased caveolin-3 mRNA in
mdx TA relative to control (Fig. 1C).
Northern blot analysis of mRNA levels in mixed leg
muscles veri¢ed these ¢ndings. The mdx muscles that con-
tained low nNOS mRNA also contained signi¢cantly in-
creased caveolin-3 mRNA (Fig. 1D). The L-actin mRNA lev-
els in Fig. 1D are shown to indicate equal loading.
To correlate Western blot data with the expression of func-
tionally intact proteins, it was necessary to determine the NOS
activity. TA homogenates were separated to membrane and
soluble fractions by centrifugation at 105 000Ug for 1 h. The
enzyme assays were performed at nearly saturating substrate
concentrations (20 WM L-arginine). The mean NOS activities
(pmol/mg/min) of six animals þ S.E.M. were as follows: con-
trol membranes 32.2 þ 4.03; control supernatants 35.4 þ 1.28;
mdx membranes, 6.8 þ 1.20; mdx supernatants, 20.8 þ 2.98.
These data show that the NOS activity is signi¢cantly re-
duced in the membrane and the soluble fractions of mdx
mouse TA muscles.
Since we assayed the same samples for NOS activity and for
NOS protein levels, it was possible to determine if the changes
in enzyme activity correlate with the changes in protein levels.
Fig. 2 shows that the changes in mdx TA NOS activity cor-
relate with the changes in NOS proteins. This suggests that
the reduced enzyme activity in mdx muscles is due to the
reduced enzyme levels. Fig. 2 also shows that nNOS and
caveolin-3 protein levels change in the opposite way in the
same mdx muscles.
4. Discussion
Our data showing increased caveolin-3 mRNA and protein
levels in mdx mouse muscles are in agreement with the in-
creased number of caveolae in dystrophin-de¢cient muscles
[11,12]. We suggest that the induction of caveolin-3 could at
least partly be responsible for this structural change.
Recent studies have determined that the activities of calci-
um-dependent NOS isoforms are regulated not only by calci-
um and calmodulin but also by caveolins. While binding of
the calcium-calmodulin complex activates these enzymes, the
binding of caveolins inhibits them [2,5,6,19]. This suggests the
operation of a NOS-caveolin cycle that involves reversible
binding and inhibition of NOS with caveolin depending on
the cytosolic calcium concentrations [2,19]. The reciprocal
change in nNOS and caveolin-3 may have an e¡ect on the
NOS-caveolin cycle in dystrophic muscles where cytosolic cal-
cium is known to be increased.
Dystrophin de¢ciency results in the depletion of several
associated proteins [9] and nNOS appears to be one of them
[20]. In contrast to humans where regeneration is ine⁄cient,
the regeneration is extensive and e⁄cient in mdx mice and this
results in a mild phenotype [13]. The successful regeneration
in the absence of dystrophin could be due to induction of
utrophin expression in mdx mice [14,21^24]. The induction
of caveolin-3 in mdx mouse muscles may also be an indication
of di¡erentiation and regeneration. This hypothesis is in
agreement with data showing that caveolin-3 is substantially
induced during di¡erentiation of skeletal muscle myoblasts in
culture [4] and that the density of caveolae is preferentially
increased in regenerating muscles [12].
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